C3 Glomerulopathy by Kojc, Nika
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
C3 Glomerulopathy
Nika Kojc
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.79768
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
 l r l t
Nika Kojc
Additional information is available at the end of the chapter
Abstract
Understanding the role of alternative complement pathway dysregulation in membra-
noproliferative glomerulonephritis (MPGN) has led to a new classification into two sub-
groups: immune complex-mediated MPGN and complement-mediated MPGN. Immune 
complex-mediated MPGN results from the deposition of immunoglobulin deposits and 
complements component C3 driven by classical complement pathway activation, while 
complement-mediated disease may be associated with complement alternative pathway 
dysregulation and is a new entity, C3 glomerulopathy. C3 glomerulopathy is an umbrella 
term, encompassing dense deposit disease (DDD), former MPGN type II, and C3 glomeru-
lonephritis. C3 glomerulonephritis comprises examples of MPGN types I and III, in which 
immunofluorescence reveals predominant C3 deposits. By light microscopy, distinctive his-
tologic patterns can be observed in both entities, including membranoproliferative, mesan-
gial proliferative, crescentic and acute proliferative and exudative patterns, of which the 
membranoproliferative pattern seems to be the most common. DDD is defined by the pres-
ence of dense osmiophilic transformation of the glomerular basement membrane (GBM) on 
electron microscopy (EM). Only EM enables definite distinction of DDD from C3 glomeru-
lonephritis. C3 glomerulopathy is a heterogeneous disease; genetic or acquired complement 
alternative pathway abnormalities have been identified in up to 40% of patients, including 
mutations in complement factors or autoantibodies directed against them.
Keywords: C3 glomerulopathy, C3 glomerulonephritis, dense deposit disease, 
membranoproliferative glomerulonephritis, complement alternative pathway 
dysregulation, complement regulation, CFHR5 nephropathy, C3 nephritic factor, 
eculizumab
1. Introduction
C3 glomerulopathy is a recently defined glomerular disease, characterized by predominant 
C3 complement component (C3) deposits in the glomeruli in the absence of a significant 
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amount of immunoglobulin and without deposition of C1q and C4. The accumulation of C3 
without a significant amount of classical or lectin complement component in the glomeruli 
suggests dysregulation of the alternative complement pathway as the underlying pathoge-
netic mechanism.
Glomerular C3 deposits confirmed by immunohistochemistry correspond to electron dense 
deposits seen on electron microscopy (EM). By light microscopy, distinctive histologic pat-
terns can be observed, including membranoproliferative, mesangial proliferative, crescentic 
and acute proliferative and exudative patterns, of which the membranoproliferative pattern 
seems to be the most common [1–3]. The recognition of C3 glomerulopathy led to a major 
revision of the understanding of the entity of membranoproliferative glomerulonephritis 
(MPGN) [1, 4, 5].
2. Historical overview of membranoproliferative glomerulonephritis
Rather than a disease, MPGN is a morphologic pattern of glomerular injury, characterized on 
light microscopy by mesangial hypercellularity and thickening of the capillary walls, result-
ing in glomerular capillary wall remodeling. In the active phase, a proliferative and exudative 
pattern predominates, whereas in the reparative phase, mesangial expansion occurs, together 
with double contour formation and mesangial interposition seen on EM [6, 7].
Without knowledge of the pathogenesis, MPGN was traditionally classified based on histo-
logic features defined by light microscopy and the location of the deposits as observed by 
EM. Three types of MPGN were recognized: MPGN types I, II and III [7–9].
MPGN type I was characterized by mesangial and subendothelial deposits, with marked 
mesangial interposition and double contour formation (Figure 1) [9]. Type III, defined by 
mesangial, subendothelial and subepithelial deposits, was further subdivided into two vari-
ants: the Burkholder variant and Anders-Strife variant, describing different patterns of electron 
dense deposits and disorganization of the glomerular basement membrane (GBM) [8, 10]. In the 
Burkholder variant, there were discrete subendothelial and subepithelial deposits (Figure 2), 
while in the Anders-Strife variant, the deposits produced complex transmembranous, ribbon-
like subendothelial and subepithelial deposits with fraying of the lamina densa (Figure 3).
MPGN type II was first described by Berger and Galle in 1963 as a dense deposit disease 
(DDD) characterized by extremely electron dense transformation of the GBM (Figure 4) [11]. 
Little attention was paid to this entity until 1975, when Habib indicated an association between 
dense transformation of the GBM and the MPGN histologic pattern and therefore classified it 
as a type II variant of MPGN, which was followed by long-term consequences [12].
From the beginning, an MPGN lesion delineated a group of patients with no evidence of 
underlying disease—an idiopathic MPGN [9, 13]. Over time, as serological and other meth-
odology improved, many secondary forms with clear etiologic associations were differenti-
ated from idiopathic MPGN. It became apparent that MPGN is often associated with chronic 
infections (hepatitis B and C, with or without cryoglobulinemia), autoimmunity or deposition 
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of a monoclonal immunoglobulin. A histologic pattern resembling the MPGN pattern could 
also be observed in a broad group of thrombotic microangiopathy: thrombotic thrombocy-
topenic purpura, atypical hemolytic uremic syndrome (aHUS), sickle cell anemia, diabetic 
glomerulosclerosis, transplant glomerulopathy and malignant hypertension [7, 14, 15]. In this 
group of diseases, there is little or no proliferation and neither marked mesangial interpo-
sition nor immune deposits are detected on immunofluorescence (IF) or EM. GBM double 
contours occur due to subendothelial neolamina formation in response to insudative changes, 
endothelial swelling and subendothelial plasma insudation.
This historical classification, based on histologic and ultrastructural findings and devoid of patho-
genetic context, could not explain the diversity of underlying pathogenetic mechanisms, nor the 
various clinical pictures in MPGN patients [13]. It was tempting to speculate that other features, 
in addition to the peculiar description of deposits location, would clarify at least some group of 
Figure 1. MPGN type I is characterized by mesangial and subendothelial deposits, with marked mesangial interposition 
and double contour formation.
Figure 2. Burkholder variant of MPGN type III shows mesangial and discrete subendothelial and subepithelial deposits.
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patients with features of MPGN [14, 16, 17]. The discovery that many children with DDD displayed 
persistent hypocomplementemia, with low levels of serum complement factors, was a harbinger 
of the identification of the heterogeneity of mechanisms underlying the MPGN pattern [17].
It was increasingly observed that many patients with dense deposits on EM, characteristic of 
MPGN type II lacked a MPGN pattern on light microscopy [18]. In order to disprove the rela-
tion between dense transformation of GBM and a MPGN histologic pattern, Walker collected 
69 cases of DDD from centers in North America, Europe and Japan [19].
Surprisingly, four histologic patterns were identified: membranoproliferative, mesangial pro-
liferative, crescentic, and acute proliferative and exudative. The MPGN pattern was found 
only in 25% of cases; the majority of patients presented with mesangial proliferative features. 
On light microscopy and IF, the acute proliferative and exudative variants can be difficult to 
distinguish from post-infectious glomerulonephritis [20, 21].
Figure 3. In Anders-Strife variant of MPGN type III, the deposits produce complex transmembranous, ribbon-like 
subendothelial, and subepithelial formations with fraying of the lamina densa.
Figure 4. Highly electron dense intramembranous and mesangial deposits are hallmark of DDD, classified historically 
as MPGN type II.
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Concurrently, improving IF techniques enabled differentiation of the composition of the 
deposits detected by IF [9, 22]. Biopsies from patients with MPGN type II usually showed 
only C3 deposits, with little or without immunoglobulin deposition. Furthermore, even in 
some cases of MPGN types I and III, pathologists noticed the presence of dominant comple-
ment deposits, therefore setting these cases apart from more common variants of type I 
and III containing immunoglobulins and C3. These cases were initially called idiopathic 
MPGN with dominant C3 deposits [13, 23]. Moreover, patients with MPGN and dominant 
C3 deposits also presented with low serum C3, indicating complement alternative path-
way dysregulation, while serum levels of classical complement factors were mainly normal. 
Laser micro dissection and mass spectrometry data of glomeruli from DDD and MPGN 
with dominant C3 deposits showed a similar proteomic profile, indicating a common patho-
genesis of the two diseases [24, 25]. A major breakthrough was the discovery of genetic 
mutations or deficiencies in complement regulatory proteins in patients with predominant 
C3 deposits [14, 26].
2.1. Proposal for a new classification
The aforementioned elucidations of the possible pathogenesis of MPGN led to a new clas-
sification based on the composition of deposits: into immune complex-mediated and comple-
ment-mediated diseases [2, 4, 5, 27, 28].
Figure 5. The evolving classification of MPGN: the composition of the deposits seen on IF categorized MPGN as immune 
complex-mediated and complement-mediated disease, the later termed C3 glomerulopathy. Immune complex-mediated 
MPGN without known underlying cause (idiopathic MPGN) may be immune complex-mediated at the beginning, 
evolving into C3 glomerulopathy over time. MPGN membranoproliferative glomerulonephritis, IF immunofluorescence.
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Immune complex-mediated MPGN results from the deposition of immunoglobulin deposits 
and C3 driven by classical complement pathway activation, while complement-mediated 
disease may be associated with complement alternative pathway dysregulation and is a new 
entity, C3 glomerulopathy. C3 glomerulopathy is characterized by predominant C3 deposits 
on IF (Figure 5) [5, 9, 29].
C3 glomerulopathy is an umbrella term, encompassing DDD (former MPGN type II) and 
examples of MPGN types I and III, in which IF reveals exclusive or predominant C3 deposits, 
now termed C3 glomerulonephritis (C3GN) [4, 5, 22, 29, 30]. DDD is defined by the presence 
of dense osmiophilic transformation of the GBM on EM. Only EM enables definite distinction 
of DDD from C3GN; however, a spectrum of appearances may be seen in some cases, even in 
the same glomerulus.
3. Diagnosing C3 glomerulopathy
Cases with a membranoproliferative pattern that have only glomerular C3, with absolutely no 
immunoglobulin, are relatively uncommon; most cases will have dominant C3 staining with 
some immunoglobulin. The original definition of C3 glomerulopathy as “C3 only” appeared 
too stringent if the goal of diagnosis is to identify all complement-mediated cases for evalua-
tion of complement alternative pathway dysregulation [2, 28, 30, 31].
In a study of over 300 cases of idiopathic MPGN, Hou et al. applied a hierarchical set of 
criteria to define the optimal cut-off for a diagnosis of C3 glomerulopathy, using DDD as a 
gold standard [22]. A new definition of C3 glomerulopathy was therefore proposed, for when 
C3 dominance is at least two orders of magnitude stronger than any other immune reactant. 
The new definition identified 31% of MPGN type 1, 88% of DDD (MPGN type II) and 39% of 
MPGN type III cases, indicating a sensitivity of 88% and acceptable specificity.
In terms of the modern approach to MPGN, 39% of the Anders-Strife variant would be clas-
sified as C3GN, whereas the majority of the Burkholder variant and approximately 70% of 
MPGN type I presented with immunoglobulin and C3 deposits as immune complex-medi-
ated MPGN [22]. In many of those cases, an underlying cause could be identified, such as 
autoimmunity, chronic infection or deposition of a monoclonal immunoglobulin, indicating 
that idiopathic MPGN might now be considered a rare condition. It encompasses histori-
cal MPGN types I and III with immunoglobulin and complement deposits without known 
underlying cause [9, 31].
However, such rare cases might represent C3GN with immunoglobulin deposits, which did 
not fulfill the diagnostic criteria for C3 glomerulopathy at the time of diagnosis, and therefore 
an underlying complement dysregulation has to be excluded [31, 32].
It has already been proposed that, in some patients, immune complexes may initiate MPGN, 
but the disease is accelerated and sustained by complement alternative pathway dysregulation 
[30]. When a complement activating infection occurs, it may overwhelm the compensatory 
regulatory mechanisms, leading to augmented and perpetuated activation of dysregulated 
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complement alternative pathway. MPGN may therefore be immune complex-mediated at the 
beginning, evolving into C3 glomerulopathy over time (Figure 5).
Although the proposed classification seems to be widely accepted, a recent study indicates 
that understanding MPGN by classification into immunoglobulin-mediated and C3 domi-
nant forms might be too simplistic and may not provide sufficient information on prognosis 
and prevention of the disease [33]. In the future, novel research methods, probably based on 
mathematical models, will be employed in order to provide detailed insights into manage-
ment of C3 glomerulopathy [33].
4. Dense deposit disease
4.1. Clinical presentation
DDD is a rare disease, with a reported incidence between 2 and 3 per million of the popula-
tion, primarily affecting children and young adults, although the range is broad, varying from 
1 to 64 years [19]. Recently, a study with the largest American cohort to date, including 111 
patients with C3 glomerulopathy, 24 of them with DDD, found 29% of patients older than 
50 years [3]. Males and females are usually equally involved, but some studies have reported 
a female predominance [1].
The clinical presentation is usually unspecific, with a slow deterioration of renal function. In 
the past, approximately 50% of patients presented with nephrotic syndrome at the time of 
diagnosis [12, 34, 35]. A recent study showed that most patients displayed proteinuria and 
hematuria with preserved kidney function, although about 25% of patients showed significant 
chronic kidney disease at the time of diagnosis [3]. Acute, often a respiratory tract infection 
prior to DDD onset was reported in approximately half of the patients, and this did not differ 
between pediatric and adult populations [1, 3, 12]. Progression to ESRD has been reported in 
up to 50% of patients within 10 years of diagnosis [2, 36].
Approximately 65–80% of patients with DDD present with persistently low serum C3 but 
serum levels of the early classic pathway components C1q and C4 are usually normal [1–3, 12]. 
Pediatric patients had lower C3 levels than adults [1, 3]. Up to 80% of patients with DDD 
showed positive serum C3 nephritic factor (C3Nef), an autoantibody directed against alterna-
tive pathway convertase, although it is not specific and is also found in patients with MPGN 
type I, post-infectious glomerulonephritis and even lupus nephritis [2, 35, 37–40]. Other 
autoantibodies against complement factors, including anti factor H antibody, anti-factor B 
antibody and complement factor gene variant and mutations have been found in various 
percentages of DDD patients [2, 3].
Rarely, patients with DDD may present with two other conditions, either separately or 
together: ocular drusen or acquired partial lipodystrophy. Both conditions are associated 
with dysregulation of the alternative complement pathway [14, 19, 41].
Ocular drusen are yellow deposits localized between the retinal pigment epithelium and 
Bruch’s membrane, consisting of lipoproteinaceous deposits of complement-containing 
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debris [42, 43]. Similar drusen are found in patients with age-related macular degeneration 
(AMD) but in contrast to patients with AMD, drusen in DDD patients occur at an early age. 
The same polymorphisms in factor H have been identified in patients with AMD and DDD, 
implicating AP complement dysregulation in the pathogenesis of both diseases [41, 44].
DDD can be rarely associated with acquired partial lipodystrophy (APL), the symmetrical 
loss of subcutaneous fat in the upper half of the body (face, arms and upper part of the trunk) 
[45]. Approximately 20% of patients with APL develop MPGN. APL usually precedes the 
onset of kidney disease by several years. Frequent detection of C3Nef and low C3 level in 
these patients indicates an underlying dysregulation of AP complement on both kidneys and 
adipose tissue. The deposition of activated complement factors in adipose tissue may result 
in the destruction of adipocytes [45].
4.2. Pathologic findings
4.2.1. Light microscopy
A specific feature of DDD is the presence of dense osmiophilic transformation of the GBM 
on EM [19, 20]. Due to the association between dense GBM transformation and an MPGN 
histological pattern described decades ago, it was classified historically as MPGN type II [12]. 
However, the appearance of DDD on light microscopy is quite variable, showing membrano-
proliferative, mesangial proliferative, crescentic and acute proliferative, and exudative histo-
logic patterns [1, 20]. In some cases, glomeruli show prominent endocapillary hypercellularity 
with exudation of neutrophils reminiscent of post-infectious glomerulonephritis, while others 
present with a prominent crescent formation. In an American cohort of 24 patients, mem-
branoproliferative and mesangial patterns were demonstrated in 46 and 29% of patients, 
respectively [3]. The clinical significance of the different patterns needs further evaluation, 
but in some patients, it might depend on the timing of the biopsy; patients with long-lasting 
disease may develop chronic glomerular changes with double contours characteristic of a 
membranoproliferative pattern.
On light microscopy, GBM dense deposits are recognized as thickening of the glomerular cap-
illary walls by ribbon-like intramembranous deposits. They are intensely periodic acid-Schiff 
(PAS) positive and stain strongly fuchsinophilic (red) with trichrome stain. Methenamine 
silver staining discloses characteristic defects in the GBM because dense deposits are not 
argyrophilic and therefore fail to stain with silver stains. Thin, silver-positive lines border the 
GBM on each side, resulting in typical double contours (Figure 6). Although light microscopy 
in typical cases is fairly characteristic, the glomerular intramembranous deposits may vary in 
size and number and a definitive diagnosis can be established only by EM [20, 32].
4.2.2. Immunofluorescence
DDD is characterized by the presence of intense C3 deposits in the glomerular mesangium, as 
well as along capillary walls, with minimal or no immunoglobulin deposition. There are usu-
ally abundant mesangial C3 deposits, described as coarse granules, spherules or small rings 
(Figure 7). The IF pattern along the glomerular capillary walls is described as pseudolinear, 
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smooth, ribbon-like or coarsely granular. Classical complement components and immuno-
globulin staining are usually absent; if present, they stain less intensely than C3 and may 
be focal and segmental [20, 34]. C3 deposits may be also found in the basal lamina of the 
Bowman capsule and along the tubular basement membranes of proximal and distal tubules.
4.2.3. Electron microscopy
DDD is characterized by the presence of dense transformation of the GBM found by EM. This 
special appearance of the lamina densa may be continuous and diffuse in distribution 
(Figure 4) or interrupted and fusiform, with native GBM found between deposits (Figure 8). 
In less severe cases, dense deposits may be focal, affecting only a few loops. The deposits 
Figure 6. Extensive mesangial deposits and thickening of the glomerular capillary walls by ribbon-like intramembranous 
deposits. Deposits stain strongly fuchsinophilic (red) with trichrome stain. Methenamine silver staining discloses 
characteristic defects in the GBM. (silver and trichrome stain—Jones and Azan, 400×).
Figure 7. Intense ring-like C3 deposits in the glomerular mesangium and pseudolinear along capillary walls in DDD.
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may replace the entire width of the lamina densa, whereas in less extensive involvement they 
occupy only part of the GBM width (Figure 8). Mild cases may present only in the inner (sub-
endothelial) aspect of the GBM. Subendothelial electron dense deposits sometimes evolve to 
more hyaline transmembrane deposits, with a lower electron density found in C3GN [18, 20, 
34]. Many patients show subepithelial electron dense deposits, in some cases reminiscent of 
hump-like deposits seen in post-infectious glomerulonephritis.
In addition to glomerular deposits, electron dense transformation has been described in the 
basement membrane of Bowman’s capsule and renal tubules, although usually focal and seg-
mental [1, 12, 19, 34]. Dense electron change has also been found in the afferent arterioles and 
the area of the macula densa [12].
It is noteworthy that drusen, a characteristic pathologic finding in the Bruch’s membrane in 
patients with DDD, and macular degeneration have the same ultrastructural appearance as 
the GBM in DDD [42]. Except for a report of electron dense transformation in the sinusoidal 
BM of the spleen in two patients with DDD, in no other organ systems have similar electron 
dense deposits been identified so far [46, 47].
The exact ultrastructure of electron dense deposits and the mechanism of unique GBM trans-
formation remain to be elucidated. The three-dimensional ultrastructural findings of GBM 
in DDD patients suggest rigid and thickened GBM with a coarsely granular or undulating 
surface punctuated by single or clustered crater-like deformities unique to DDD [48].
5. C3 glomerulonephritis
C3 glomerulonephritis is characterized by exclusive or predominant C3 deposits on IF and 
electron dense mesangial and glomerular capillary walls deposits on EM, without electron 
dense osmiophilic transformation of the GBM characteristic of DDD. It encompasses exam-
ples of historical MPGN types I and III and other histological patterns in which IF reveals 
Figure 8. In less extensive cases of DDD deposits occupy only part of the GBM width.
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dominant C3 deposits, indicating complement alternative pathway dysregulation as the 
underlying pathogenetic mechanism [24].
5.1. Clinical presentation
C3GN is a heterogeneous disease with respect to pathogenesis, clinical course and progno-
sis. Numerous mutations and polymorphisms in genes that code for proteins involved in 
complement alternative pathway and acquired abnormalities have been identified in patients 
with C3GN. There are two examples of familial forms of the disease with specific mutations, 
including CFHR5 nephropathy endemic in Cyprus and familial MPGN from Ireland [49, 50].
A recent study of a diverse American cohort including 111 patients with C3 glomerulopathy 
provided detailed information on the clinical presentation of C3GN and DDD [3]. Whites 
comprised the majority of C3GN patients (63.2%), followed by Hispanic, Asian and African-
American patients, accounting for 19.5, 12.6 and 4.6% of the cohort, respectively. Surprisingly, 
patients with C3GN (mean age 28.3) were significantly younger than patients with DDD 
(mean age 40.0 years). The most common clinical presentation was hematuria and proteinuria 
with normal kidney function in both groups, but chronic kidney disease with proteinuria and 
hematuria was more frequent in DDD patients (41.7% in DDD vs. 18.6% in C3GN). Patients 
with C3GN more often presented with nephrotic syndrome than did DDD patients (32.6 vs. 
16.7%). The prevalence of low complement level was the same in both groups, although the 
pediatric population demonstrated a significantly higher prevalence of low C3 levels and 
twice the rate of detectable genetic variants and/or autoantibodies.
Progression to end-stage renal disease (ESRD) was found in 40% of C3G patients, with no 
detectable difference between those with C3GN versus DDD, although previous reports have 
suggested a more favorable clinical course in C3GN patients [2, 26, 51, 52]. Markers of chro-
nicity, whether clinical (reduced estimated glomerular filtration rate (eGFR), elevated serum 
creatinine) or histologic (interstitial fibrosis, glomerulosclerosis) at the time of diagnosis 
appeared the strongest predictors of outcome.
5.2. Pathologic findings
5.2.1. Light microscopy
C3GN is defined by dominant C3 deposits on IF and deposits on EM. The light microscopic 
features are variable, including mesangial proliferation, a membranoproliferative pattern, 
crescent formation and endocapillary hypercellularity (Figures 9–11). There is no known 
association of the various histologic patterns with the underlying genetic or functional abnor-
malities of complement dysregulation [3, 24].
Bomback proposed a C3 Glomerulopathy Histologic Index to score biopsy activity and chro-
nicity, in order to determine predictors of progression to ESRD in patients with C3GN [3, 24]. 
The activity score included mesangial hypercellularity, endocapillary hypercellular-
ity, membranoproliferative morphology, leukocyte infiltration, crescent formation, 
fibrinoid necrosis and interstitial inflammation, while the chronicity score encompassed 
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Figure 10. C3GN with membranoproliferative pattern with exudation of neutrophils (HE, 200×).
Figure 11. C3GN with membranoproliferative pattern with abundant transmembranous deposits staining with 
trichrome stain reminiscent of DDD (Trichrome stain, 600×).
Figure 9. C3GN with membranoproliferative pattern (HE, 400×).
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glomerulosclerosis, tubular atrophy/interstitial fibrosis and arterio-arteriolosclerosis. Patients 
with C3GN showed a higher activity score than DDD patients, and the latter revealed a higher 
chronicity score. In multivariable models, the strongest predictors of progression were eGFR 
at the time of diagnosis and tubular atrophy/interstitial fibrosis. The C3 Glomerulopathy 
Histologic Index might emerge as a useful tool for predicting the prognosis and management 
of patients with C3 glomerulopathy [3].
5.2.2. Immunofluorescence
The defining feature on IF is the presence of dominant C3 glomerular deposits, at least two 
orders of magnitude stronger than any other immune reactant. It is noteworthy that a pro-
posed cut-off does not encompass all patients with alternative pathway dysregulation, and 
there are overlaps between C3GN and immune complex glomerulonephritis [27, 29, 31].
In cases presenting with a mesangial histological pattern, C3 staining is mainly mesangial, 
while in the membranoproliferative pattern, there are abundant capillary wall as well as 
mesangial C3 deposits. In some cases, C3 staining was also found on the TBM [24, 53].
5.2.3. Electron microscopy
EM revealed electron dense deposits in the mesangium and along or within the GBM, which 
correspond to C3 deposits on IF. Consistent with the definition of C3 glomerulopathy, deposits 
are composed predominantly of complement factors, although they may show similar density 
and appear at the same locations as deposits composed of immunoglobulins and C3 [24]. In 
some cases, deposits may be less dense and less sharply demarcated than typical immune com-
plex deposits (Figure 12). In the glomerular capillary walls, there are abundant transmembrane 
deposits that appear to replace areas of the lamina densa, separated by material of similar den-
sity as the lamina densa, similar to the Anders Strife variant of MPGN type III (Figure 13). In 
some cases, there are curvilinear deposits of more electron dense material in the mesangium and 
Figure 12. Abundant transmembrane deposits in C3GN may be less dense and less sharply demarcated than typical 
immune complex deposits.
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Figure 13. Abundant transmembrane deposits that replace areas of the lamina densa, separated by material of similar 
density as the lamina densa, similar to the Anders Strife variant of MPGN type III.
beneath the endothelium, reminiscent of deposits in DDD. Occasional cases display substantial 
overlapping features between DDD and C3GN, making the subcategorization difficult [32].
Many C3GN patients present with subepithelial deposits. They may sometimes appear as 
subepithelial projections of intramembranous deposits but, in some cases, they resemble typi-
cal subepithelial humps seen in post-infectious glomerulonephritis. It is tempting to speculate 
that they may be related to C3GN exacerbated by infections [21].
6. Overview of the complement system
The complement system is a complex cascade in which proteolytic cleavage of glycoproteins 
induces an inflammatory response, phagocyte chemotaxis, opsonization, and cell lysis. It is 
triggered through three different pathways: the classical, alternative and mannose binding 
lectin, which converge on C3 to form an enzyme complex C3 convertase. C3 convertase cleaves 
C3, generating C3a, an anaphylatoxin, and C3b, a potent opsonin. A positive feedback loop, 
termed the C3 amplification loop, enables rapid amplification of C3b, which can generate 
millions of C3b molecules. C3b then deposit on cell surfaces, triggering complement cascade 
activation. Through the binding of an additional C3b molecule, C3 convertase becomes C5 
convertase (C3bBbBB), which is capable of cleaving complement C5 into C5a and C5b. C5b, 
through sequential interaction with complements C6, C7, C8 and C9, generates membrane 
attack complex (MAC) [32, 54, 55].
In contrast to classical and lectin pathways, the alternative pathway is continually active in the 
circulation, by spontaneous hydrolysis of an internal thioester bond in C3 (thick over mecha-
nism). Hydrolyzed C3 interacts with complement factor B (CFB) to form C3iB. CFB within 
C3iB is cleaved by complement factor D, resulting in C3 convertase (C3iBb), which cleaves 
C3 to a small amount of C3b. Cleaved C3b, similar to C3i, interacts with complement factors 
B to form C3 convertase (C3bBbBB). If the generation of C3 is not tightly regulated, it can 
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be rapidly amplified through a positive feedback pathway (C3b amplification loop), which 
results in activation of downstream convertase C5 and MAC formation. Several complement 
degradation products, including iC3b, are delivered to the endothelial surfaces, including the 
glomeruli. The deposition of complement products in the mesangium and in the subendothe-
lial region triggers glomerular inflammation, leading to GN, often with a MPGN pattern [32].
Complement regulation is achieved by complement activator proteins and regulatory proteins 
present in plasma (fluid phase) and on cell surfaces (solid phase). Both regulate complement 
activation at different steps and pathways. If complement activator proteins are deficient, 
there is too little complement and these patients predispose to infections and autoimmune 
diseases. In regulatory protein deficiency, the complement system is upregulated, which 
results in impaired regulation and too much complement. Due to spontaneous activation of 
the alternative pathway and potency of the C3b amplification loop, both pathways are tightly 
regulated by complement factor I (CFI) and complement factor H (CFH) [30, 56].
Fluid phase regulators include factors CFH and CFI, whereas decay accelerating factor (DAF, 
CD55), complement receptor 1, CD 59 and membrane cofactor protein (MCP), are cell-bound 
regulators that act on cell surfaces [30]. Dysregulation between activating and regulatory fac-
tors in the fluid phase results in permanent activation of C3 convertase and at least partial 
activation of downstream complement factors, including C5 convertase and other proteins of 
the terminal complement cascade.
6.1. Complement factor I
CFI is a serine protease that cleaves C3b to iC3b and C3. While C3b can form C3 convertase, 
iC3b and C3d cannot, so the CFI-mediated cleavage of C3b stops further C3b activation. CFI 
can cleave C3b in the presence of cofactors, including CFH, membrane-bound protein (CD 46) 
and complement receptor 1 (CR1, CD35). In CFI deficiency, the spontaneous activation of the 
AP and, consequently, C3b amplification continue uncontrolled, leading to severe depletion 
of C3 in the plasma. Because CFI is crucial for generation of iC3b, iC3b cannot arise in com-
plete CFI deficiency. Mice models have shown that the presence of CFI is crucial for deposits 
in the GBM and these deposits might be in the form of iC3b [30].
6.2. Complement factor H
Plasma protein CFH is the major negative regulator of the complement alternative pathway 
synthetized predominantly in the liver. It regulates C3 activation in two different compart-
ments: in plasma (fluid phase) and along surfaces (solid phase) [32].
CFH is composed of 20 short consensus repeat (SCR) domains, with two major binding sites. 
The first four amino terminal domains represent binding sites for C3 convertase, thus regulat-
ing C3 in the fluid phase. The last two carboxyl terminal domains are involved in C3 activa-
tion along surfaces (solid phase) [30].
In plasma, CFH regulates C3 activation in different ways: it blocks the formation of AP con-
vertase by binding to C3b, in order to inhibit interaction between C3b and factor B. Second, 
it accelerates the spontaneous breakdown of AP C3 convertase and is a cofactor for CFI 
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mediated inactivation of C3b to iC3b [32]. CFH deficiency results in uncontrolled C3b genera-
tion and secondary C3 depletion, but generation of C3b, iC3b and C3d is possible. In contrast, 
in complete CFI deficiency, generation of iC3b and C3d cannot occur.
CFH also regulates C3 activation along surfaces, including the renal endothelium and 
GBM. Optimal functioning of CFH requires interaction with C3b and polyanions. Through 
the terminal two carboxyl terminal domains, CFH attaches to cell surfaces and extracellular 
membranes, adding a protective mechanism to prevent complement activity on cell surfaces.
CFH is therefore involved in both fluid phase and solid phase regulation and mutation on dif-
ferent binding sites of the same regulatory protein may lead to different diseases. Mutations 
that selectively affect C3 regulation domains are associated with C3 glomerulopathy, whereas 
those affecting surface recognition domains are responsible for aHUS. In aHUS, there is 
complement-mediated damage to the renal endothelium, with consequent development of 
thrombotic microangiopathy [30, 56, 57].
Mice models provide some insights into the pathogenesis of aHUS and DDD. CFH mutations 
in aHUS affect predominantly the carboxyl terminal domains, resulting in impaired surface 
regulation, but the ability to regulate plasma C3 convertase is preserved. If the mutation 
affects the amino terminal domains, uncontrolled fluid phase C3 convertase activation occurs, 
resulting in disease analogous to DDD. Therefore, in DDD, the critical step is activation of 
C3 convertase in the fluid phase. In aHUS, the critical step is activation of C5 convertase and 
impaired surface regulation at the level of the cell membrane, in the solid phase. This solid 
phase dysregulation makes aHUS a more homogeneous disease than C3 glomerulopathy, 
with implications for prognosis and response to therapy [57].
6.3. Complement factor H-related proteins 1–5
There are five genes adjacent to the CFH gene, which encode structurally related proteins 
complement factor H-related proteins 1–5 (CFHR1–5). There are many regions of sequence 
homology across the CFH-CFHR locus that, through recombination, enables structural varia-
tions of CFHR: partial deletion or whole gene deletion or duplication, implying that these 
proteins are biologically redundant. Several combined deletions of different CFHR are found 
in various frequencies in a healthy population. The most common variant is combined dele-
tion of the CFHR1 and CFHR3 genes, presenting in 5 and 16% of Caucasian and African-
American populations, respectively [50].
Polymorphic variations within the CFH-CFHR gene locus are associated with diverse pathol-
ogies, including age-related macular degeneration (AMD), meningococcal sepsis, thrombotic 
and inflammatory kidney diseases such as aHUS and C3 glomerulopathy, and autoimmune 
diseases. The significance of homozygous deletion of CFHR1, 3 genes and the mechanisms of 
action are poorly understood. It might increase the risk of developing SLE, but is protective to 
IgA nephropathy and AMD, pathologies associated with complement deposition in affected 
tissues [41, 58, 59]. Based on a protective role for CFHR1, 3 genes deletion in IgA nephropathy, 
Malik et al. developed the hypothesis that the presence of CFHR1, 3 proteins impairs comple-
ment processing within the kidney [50].
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6.3.1. The role of CFHR5 in complement regulation
Previous reports based on in vitro studies have implicated the involvement of CFHR proteins 
in complement regulatory activity [60]. According to a recent approach, these proteins have 
no direct complement regulatory activity at physiologic concentrations, unlike CFH [32].
The investigators postulated that CFHR5 may compete with CFH for binding to activated 
C3b. If CFH binds, C3b is inactivated, preventing further complement activation. Conversely, 
if CFHR binds to activated C3b, this prevents CFH binding, therefore enabling C3 convertase 
formation and continued complement activation. Since these proteins are devoid of intrinsic 
regulatory complement activity, this has been termed CFH deregulation [61].
CFHR1, CFHR2, and CFHR5 have recently been shown to form homodimers and heterodi-
mers via common dimerization domains within SCR1 and SCR2 [62]. The dimerization of 
CFHR1, CFHR2 and CFHR5 may enhance the avidity of these proteins for ligand in vivo, 
thereby preventing CFH binding and thus functioning as complement deregulators [62].
The deregulation hypothesis could also explain the protective effect of CFHR1, 3 genes 
deletion in IgA nephropathy. Fewer CFHRs in serum could lead to less CFH deregulation, 
enabling tighter control of complement activation and inflammation. Conversely, circulating 
CFHR proteins 1 and 5 may correlate with increased disease activity, as shown in a large 
cohort of patients with IgA nephropathy [63].
6.4. Membrane cofactor protein
MCP is a surface-bound complement regulatory protein acting as a cofactor for the CFI 
mediated cleavage of C3b to iC3b on the cell surface. Polymorphism in the promoter region 
may influence MCP expression at the cell surfaces, which may explain the various patterns 
of deposits in C3G [2]. The majority of mutations in CD46 are detected in the extracellular 
domains of CD46 responsible for C3b and C4b binding.
7. Familiar forms of C3 glomerulopathy
7.1. CFHR5 nephropathy
Heterozygous mutations in CFHR5 are characteristic findings in complement factor H-related 
protein 5 nephropathy (CFHR5 nephropathy) [49, 64]. CFHR5 nephropathy is a subtype of 
C3GN, with autosomal dominant inheritance discovered in Cypriot families. A heterozygous 
mutation in CFHR5 results in duplication of the first two protein subunits, termed short con-
sensus repeat. Affected individuals possess both the wild-type nine-domain CFHR5 protein 
and an abnormally large mutant CFHR5, with 11 domains [64].
Clinically, patients present with microscopic hematuria, proteinuria and synpharyngitic 
macroscopic hematuria similar to IgA nephropathy. There is progression to end-stage renal 
disease over the age of 50, particularly in males. Renal biopsies show deposition of C3 in the 
C3 Glomerulopathy
http://dx.doi.org/10.5772/intechopen.79768
161
mesangium, and characteristic elongated subendothelial electron dense deposits, and occa-
sional subepithelial deposits. The laboratory profile of patients is normal, without decreased 
C3 levels, indicating that the complement activation occurs locally in the kidney and not at 
a systemic level. It has been speculated that abnormal CFHR5 in CFHR5 nephropathy may 
prevent CFH mediated regulation of C3, leading to increased activation of C3 along the glo-
merular basement membrane [64].
7.2. Other familiar forms of C3 glomerulonephritis
Recently, an abnormal CFHR5 protein in a family without Cypriot ancestry, identical to the 
aberrant CFHR5 protein found in Cypriot CFHR5 nephropathy, was identified, related to 
familial C3 glomerulonephritis. The clinical characteristics of the nephropathy in this pedi-
gree were remarkably similar to Cypriot CFHR5 nephropathy: the typical presentation was 
with microscopic and intermittent macroscopic hematuria, and renal disease was more severe 
in affected males [65]. The genomic rearrangement was distinct from that seen in Cypriot 
CFHR5 nephropathy, although identical protein was identified.
A duplication of SCR 1–4 of CFHR1 was revealed in another familial form of C3G [66]. In 
mutant CFHR1, duplication of the N-terminal domain resulted in the formation of unusu-
ally large multimeric CFHR complexes that exhibited enhanced binding of mutated CFHR1 
to ligands C3b, iC3b and C3d, resulting in enhanced competition and replacement of CFH 
bound to C3b. Patients usually presented with decreased C3 plasma levels, suggesting fluid 
phase complement activation and systemic disease.
8. Genetic and acquired abnormalities of complement associated 
with C3 glomerulopathy
C3G is associated with genetic and acquired abnormalities that result in uncontrolled activa-
tion of the complement alternative pathway. With the exception of diacilglicerol kinase epsi-
lon, all genes associated with C3 glomerulopathy encode proteins in the complement system 
[67]. Mutations in complement factors and complement regulators are rare, but certain genetic 
polymorphisms contributing to fine balancing of complement regulation are more common.
Due to the complexity of the disease, C3 glomerulopathy is rarely inherited in a simple 
Mendelian fashion [68]. Rare familial cases of C3 glomerulopathy comprise highly penetrant 
heterozygous copy number variants involving CFHR1–5 genes described in Cypriot families, 
a family of Irish ancestry and a recently described family of non-Cypriot origin [49, 65, 66].
Most pathogenic variants of the C3 gene affect the proper cleavage of C3 protein by affect-
ing recognition sites for binding of CFH or CFI. Loss-of-function changes in CFH, gain-of-
function changes in C3 and structural changes within the CFH-CFHR gene family have been 
identified [69].
Acquired abnormalities include antibodies to complement activating proteins, such as 
antibody to C3 convertase, and antibodies which target the inhibitory complement factors 
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(CFH or CFI autoantibodies). C3Nef, antibody to C3 convertase, stabilizes C3 convertase of 
the alternative pathway by preventing its inactivation and degradation. Recent studies have 
shown that some autoantibodies might arise due to underlying genetic abnormalities [68].
In the largest study to date, encompassing 134 patients, Servais et al. analyzed the presence 
of C3Nef and other genetic and acquired abnormalities in patients with DDD, C3GN and 
primary MPGN type I [2]. C3Nef was identified in 86% of patients with DDD, but it was 
also present in 24% of GNC3 patients and even in 53% of patients with primary MPGN type 
I. CFH mutations were found in a similar frequency in all three groups of patients. MCP 
mutations seem to be very rare, identified in only one patient with C3GN. Another very 
interesting report described three patients with known homozygous CFH deficiency, who 
presented with different histological patterns, varying from mesangial proliferative to mem-
branoproliferative [70]. Studies from rare cases with known genetic abnormalities indicate 
that entities with predominant C3 deposits, DDD and C3GN, as well as immune complex 
MPGN, are heterogeneous diseases.
Genetic or acquired complement AP abnormalities have also been identified in association 
with immune complex-mediated glomerulonephritis, such as systemic lupus erythematosus, 
and particularly frequently in patients with immune complex-mediated MPGN and atypi-
cal post-infectious glomerulonephritis, the latter showing overlapping features with C3 glo-
merulopathy [2, 21]. The question of why some patients present with DDD while others with 
ill-defined intramembranous deposits consistent with C3GN remains to be answered. The 
processes driving the particular morphologic appearance of glomerular deposits seem to be 
very complex, including genetic and environmental factors.
9. Treatment in C3 glomerulopathy
There is no universally effective treatment for C3 glomerulopathy. The only double blind 
randomized control trial was performed on 80 children with MPGN types I, II and III in 
1992. They received 40 mg/m2 of prednisolone on alternate days. Long-term treatment with 
prednisolone appeared to improve the outcome of patients with MPGN [71]. Other studies 
have suggested some benefit from the use of cyclophosphamide, mycophenolate mofetil and 
a combination of aspirin and dipyridamole. Current guidelines suggest treatment with ste-
roids and cytotoxic agents, with or without plasmapheresis, only in patients with progressive 
disease with nephrotic range proteinuria and a decline of renal function [72]. Because C3G is 
a new diagnostic category, long-term data on renal transplants are lacking, but recurrence is 
probably as high as in idiopathic MPGN type I (up to 65% in some series).
Rituximab has emerged in the last decade as a treatment option for patients with various pri-
mary glomerular diseases. Despite data on the use of rituximab in MPGN and C3G being lim-
ited, patients with immunoglobulin-associated and idiopathic MPGN treated with rituximab 
showed a partial or complete response in the majority of cases [72]. It can be hypothesized 
that, in the presence of autoantibodies such as C3Nef, B-cell depleting therapy may have led 
to decreased production of C3Nef and, subsequently, stable renal function [72]. However, 
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rituximab was not effective in a few reported cases of C3GN and DDD. Only one patient with 
DDD and positive C3Nef treated solely with rituximab showed stable renal function and 
improvement of nephrotic syndrome after 30 months of follow-up, but C3Nef remained posi-
tive and C3 levels were always low [73]. In contrast, other cases with DDD and C3G initially 
treated with rituximab achieved partial or complete remission on eculizumab [72, 74].
Eculizumab is a humanized monoclonal antibody that binds with high affinity to C5 and 
prevents the generation of MAC and release of the very potent inflammatory mediator C5a. 
It is the treatment of choice in aHUS and paroxysmal nocturnal hematuria, but it may also 
provide an effective targeted treatment for patients with C3GN sharing an abnormality in the 
regulation of complement AP [75]. However, it has been suggested that eculizumab might 
be effective in some cases of C3GN, and that elevation of sMAC, lower circulating C3, short 
disease duration, acute lesions and limited fibrosis before treatment may predict a favorable 
response [24, 31, 76]. Eculizumab seems also to be effective in the treatment of a recurrence of 
DDD on renal transplants [76].
In patients with immune complex-mediated MPGN, refractory to conventional immunosup-
pression, the presence of complement AP dysregulation should be considered. When special 
laboratory and molecular genetic tests reveal an underlying complement alternative pathway 
dysregulation, they might respond to eculizumab treatment. Due to an initial immune com-
plex-mediated mechanism, which can mask an underlying complement alternative pathway 
abnormality and subsequently trigger unbalanced excessive complement terminal pathway 
activation, supplementary steroids, in addition to eculizumab, may be necessary to achieve 
an adequate response [53].
10. Conclusions
C3 glomerulopathy is a heterogeneous disease, recently defined by dominant C3 glomerular 
deposits on immunofluorescence suggesting dysregulation of the alternative complement 
pathway as the underlying pathogenetic mechanism. It encompasses C3GN and DDD; DDD 
is characterized by dense osmiophilic deposits on EM. The appearance on light microscopy is 
quite variable, showing membranoproliferative, mesangial proliferative, crescentic, and acute 
proliferative and exudative histologic patterns. Genetic or acquired complement AP abnormali-
ties have been identified in up to 40% of patients with C3 glomerulopathy, including mutations 
in complement factors or autoantibodies directed against them. Various clinical courses and 
histological features among patients with the same genetic defect indicate that other genetic 
factors or triggers from the environment contribute to the initiation and progression of comple-
ment mediated diseases. Despite multiple genetic risk factors, glomerular injury due to comple-
ment dysregulation often develops late in life, suggesting that additional triggers are required.
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